A recent meta-analysis reviewed 18 eligible RCTs involving 1330 participants and based on those results, SGLT-2 inhibitors were shown to slightly improve hepatic steatosis and fibrosis when compared to controls with low to moderate certainty of evidence [26]. Here, SLC5A2 is linked to fatty liver disease.